Clorox stock price target lowered to $117 by TD Cowen on ERP disruptions

TD Cowen has reduced its price target on Clorox (NYSE:CLX) to $117.00 from $120.00, maintaining a Hold rating, citing first-quarter ERP system transition disruptions and persistent organic sales weakness, leading to significantly lowered fiscal year 2026/2027 EPS and gross margin forecasts. This more cautious outlook, shared by other analysts who have revised earnings expectations downward, contrasts with Clorox's recent Q4/FY2025 earnings beat and Jefferies' maintained Buy rating with a $155 price target, which noted the ERP issues have been resolved, highlighting a divergence in analyst sentiment regarding the company's operational recovery and future performance.

Analysis

Clorox (NYSE:CLX) presents a conflicting investment picture, marked by divergent analyst sentiment following a period of operational disruption. On one hand, TD Cowen has lowered its price target to $117.00, maintaining a Hold rating, due to first-quarter service disruptions from an ERP system transition and persistent weakness in organic sales. The firm's bearish outlook is quantified by a significant reduction in its fiscal year 2026 EPS forecast to $5.19, well below the $6.11 consensus, and a projected gross margin of 40.5% that falls below Clorox's own 41-42% guidance. This cautious view is echoed by five other analysts who have recently revised earnings estimates downward. Conversely, this contrasts sharply with the company's recent strong performance, where it reported Q4/FY2025 EPS of $2.87, a 29.86% beat over the $2.21 forecast, on revenues that also surpassed expectations. This positive result underpins Jefferies' maintained Buy rating and $155 price target, with the firm noting that the challenging ERP rollout issues have now been resolved. The stock's current price of $123.30 sits between these two targets, reflecting market uncertainty over whether the operational headwinds are temporary or a more structural issue.

Key Decisions for Investors

• Investors should closely monitor Clorox's next quarterly earnings for evidence of gross margin recovery and a rebound in organic sales to validate whether the ERP-related disruptions were transitory, as Jefferies suggests, or indicative of a more persistent operational problem.
• Given the wide disparity between TD Cowen's $117 price target and Jefferies' $155 target, the stock's current trading level reflects significant uncertainty, and positions should be managed with an awareness of potential volatility as the true operational trajectory becomes clearer.
• For income-oriented investors, the 4.02% dividend yield, supported by 49 consecutive years of increases, provides a compelling reason to hold, but it is crucial to watch for any deterioration in fundamentals that could jeopardize future dividend growth or the company's ability to meet its guidance.